OS Therapies Incorporated ( (OSTX) ) has released its Q3 earnings. Here is a breakdown of the information OS Therapies Incorporated presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
OS Therapies Incorporated is a Delaware-based biotechnology company focused on developing treatments for Osteosarcoma and related diseases, with ongoing clinical trials and a subsidiary focused on animal health. In its latest earnings report for the quarter ending September 30, 2025, OS Therapies reported significant financial activity, including a net loss of $15.3 million for the nine months ended September 30, 2025, compared to a $5.9 million loss in the same period of 2024. The company’s operating expenses surged, driven by increased research and development costs and general administrative expenses. Despite the losses, OS Therapies raised $7.3 million through financing activities, including the sale of preferred stock and warrant exercises, which partially offset the cash used in operations. The company’s management remains focused on securing additional capital to continue its operations and advance its clinical trials, highlighting the importance of future financing efforts to sustain its business activities.